3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Colorectal Neoplasms
56
Ovarian Neoplasms
35
Carcinoma, Hepatocellular
35
Neoplasms
25
Fallopian Tube Neoplasms
20
Carcinoma, Non-Small-Cell Lung
19
Endometrial Neoplasms
13
Glioblastoma
11
Breast Neoplasms
11
Brain Neoplasms
11
Neoplasm Metastasis
9
Colonic Neoplasms
9
Lung Neoplasms
8
Uterine Cervical Neoplasms
7
Liver Neoplasms
7
Rectal Neoplasms
6
Glioma
6
Biliary Tract Neoplasms
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Gastrointestinal Neoplasms
4
Digestive System Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Recurrence
3
Peritoneal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Interventions
pembrolizumab
3
lenvatinib
2
Specimen Handling
2
Nivolumab
2
Cisplatin
2
trastuzumab deruxtecan
1
tivozanib
1
liposomal doxorubicin
1
entinostat
1
dostarlimab
1
bintrafusp alfa protein, human
1
atezolizumab
1
Therapeutic Touch
1
Surveys and Questionnaires
1
Radiotherapy
1
Radiation
1
Platinum
1
Paclitaxel
1
Nelfinavir
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Gemcitabine
1
Doxorubicin
1
Dehydroepiandrosterone
1
CTLA-4 Antigen
1
Bupropion
1
Blood Specimen Collection
1
Bevacizumab
1
Axitinib
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
Bevacizumab
×
90 days
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled